10-Q: AEON Biopharma Reports Q2 2024 Results, Strategic Shift to Biosimilar Pathway

AEON Biopharma announced its Q2 2024 results, highlighted by a strategic shift to pursue a biosimilar regulatory pathway for its lead product candidate, ABP-450.

Summary

• AEON Biopharma reported a net income of $164.1 million for the three months ended June 30, 2024, and $46.1 million for the six months ended June 30, 2024, a significant turnaround from losses in the same periods of 2023.
• The company is shifting its focus to a 351(k) biosimilar regulatory pathway for ABP-450, using AbbVie's Botox as a reference product, after discontinuing Phase 2 migraine trials.
• AEON plans to initiate a single pivotal clinical study for ABP-450 in cervical dystonia, contingent on raising additional capital.
• As of June 30, 2024, AEON had $3.4 million in cash and cash equivalents and an accumulated deficit of $427.5 million.
• The company has concluded that there is substantial doubt about its ability to continue as a going concern without additional financing.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's a significant net income for the quarter, the strategic shift and going concern warning raise concerns. The company's future is highly dependent on securing additional funding and the success of the biosimilar pathway.

Positives

• The company achieved a significant net income of $164.1 million for the three months ended June 30, 2024, and $46.1 million for the six months ended June 30, 2024.
• AEON is pursuing a biosimilar pathway for ABP-450, which could potentially expedite regulatory approval.
• The company has a scheduled meeting with the FDA in the third quarter of 2024 to discuss the biosimilar pathway.
• A gain of $161.2 million was recognized in the change in fair value of contingent consideration for the three months ended June 30, 2024.

Negatives

• The company has an accumulated deficit of $427.5 million as of June 30, 2024.
• AEON has concluded that there is substantial doubt about its ability to continue as a going concern without additional financing.
• Phase 2 clinical trials for episodic and chronic migraine were discontinued after not meeting primary endpoints.
• The company experienced a net cash used in operating activities of $16.7 million for the six months ended June 30, 2024.
• The company recorded a loss on forward purchase agreements and derivative liabilities of $20.0 million for the six months ended June 30, 2024.

Risks

• The company's future success depends entirely on the successful and timely regulatory approval and commercialization of ABP-450.
• Clinical product development involves a lengthy, expensive and uncertain process.
• Even if approved, ABP-450 may not achieve broad market acceptance.
• AEON relies on Daewoong for manufacturing and supply of ABP-450, and any issues with Daewoong could adversely affect the company.
• The company may face third-party claims of intellectual property infringement.
• The company will require additional capital, which may not be available on acceptable terms or at all.

Future Outlook

AEON plans to initiate a single pivotal clinical study evaluating ABP-450 in patients with cervical dystonia, with the goal of using the biosimilar pathway, subject to raising additional capital. The company will discuss the proposed biosimilar pathway with the FDA during a Biosimilar Initial Advisory Meeting scheduled for the third quarter of 2024.

Management Comments

• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern.
• The company is actively attempting to secure additional capital to fund its operations.

Industry Context

The shift to a biosimilar pathway reflects a broader trend in the pharmaceutical industry to reduce development costs and timelines by leveraging existing reference products. This approach is particularly relevant in the botulinum toxin market, where established products like Botox have a strong market presence.

Comparison to Industry Standards

• AEON's strategic shift to a biosimilar pathway for ABP-450 is a common approach for companies seeking to enter the botulinum toxin market, which is dominated by established brands like Botox (AbbVie) and Dysport (Ipsen).
• The company's decision to focus on cervical dystonia for its pivotal study aligns with the therapeutic indications of existing botulinum toxin products, such as Botox and Xeomin (Merz).
• The financial results, while showing a net income for the quarter, are overshadowed by the company's substantial accumulated deficit and concerns about its ability to continue as a going concern, which is not uncommon for clinical-stage biopharmaceutical companies.
• The company's reliance on a single supplier, Daewoong, for manufacturing is a risk factor that is common in the industry, but also highlights the importance of supply chain management and contingency planning.

Legal Proceedings

• Odeon Capital Group LLC filed a lawsuit against the Company alleging failure to pay a deferred underwriting fee of $1.25 million.

Related Party Transactions

• The company entered into a subscription agreement with Daewoong for convertible notes and amended the license agreement.

Stakeholder Impact

• Shareholders face potential dilution from future equity financings.
• Employees may be affected by potential cost-cutting measures.
• Customers and patients may experience delays in the availability of ABP-450.
• Suppliers and creditors may be impacted by the company's financial uncertainty.

Next Steps

• AEON plans to discuss the proposed biosimilar pathway with the FDA during a Biosimilar Initial Advisory Meeting scheduled for the third quarter of 2024.
• The company plans to initiate a single pivotal clinical study evaluating ABP-450 in patients with cervical dystonia, subject to raising additional capital.

Key Dates

Keywords

ABP-450, biosimilar, botulinum toxin, cervical dystonia, migraine, clinical trials, FDA, regulatory approval, Daewoong, biopharmaceutical